...
首页> 外文期刊>Clinical Rheumatology >A case of “refractory” lupus erythematosus profundus responsive to rituximab [case report]
【24h】

A case of “refractory” lupus erythematosus profundus responsive to rituximab [case report]

机译:一例对利妥昔单抗有反应的“难治性”红斑性狼疮[病例报告]

获取原文
获取原文并翻译 | 示例
           

摘要

Lupus erythematosus profundus is a rare complication of systemic lupus erythematosus characterized by the presence of deep, tender subcutaneous nodules. A 22-year-old African-American female with extensive lupus profundus resistant to conventional therapies was treated with two infusions of the anti-CD20 monoclonal antibody, rituximab, at a dosage of 1,000 mg each. The patient demonstrated a remarkable clinical response as indicated by the disappearance of the nodules. B-cell depletion therapy with rituximab used alone or in combination with other therapies may be a viable option in patients with lupus profundus refractory to current therapies.
机译:深部红斑狼疮是一种系统性红斑狼疮的罕见并发症,其特征是存在深而柔软的皮下结节。接受两次抗CD20单克隆抗体利妥昔单抗输注治疗,治疗22岁的对传统疗法具有广泛的狼疮性深部红斑狼疮的女性,每次剂量为1,000 mg。如结节消失所示,患者表现出显着的临床反应。对于目前治疗难以治疗的深部狼疮患者,单独使用利妥昔单抗或与其他疗法联用的B细胞耗竭疗法可能是可行的选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号